- Home
- PGNY
PGNY
Progyny Inc.
as of 03-06-2026 3:55pm EST
$18.28
+$0.66
+3.75%
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.5B | IPO Year: | 2019 |
| Target Price: | $27.80 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.65 | EPS Growth: | 14.04 |
| 52 Week Low/High: | $16.75 - $28.75 | Next Earning Date: | 05-18-2026 |
| Revenue: | $1,288,661,000 | Revenue Growth: | 10.40% |
| Revenue Growth (this year): | 9.57% | Revenue Growth (next year): | 10.06% |
| P/E Ratio: | 27.21 | Index: | N/A |
| Free Cash Flow: | 191.8M | FCF Growth: | +10.41% |
AI-Powered PGNY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 72.00%
72.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Progyny Inc. (PGNY)
Swartz Allison
Sell
EVP, GC
PGNY Mar 4, 2026
Avg Cost/Share
$17.54
Shares
599
Total Value
$10,506.46
Owned After
88,941
SEC Form 4
Swartz Allison
Sell
EVP, GC
PGNY Mar 3, 2026
Avg Cost/Share
$17.40
Shares
4,657
Total Value
$81,029.80
Owned After
88,941
Swartz Allison
Sell
EVP, GC
PGNY Mar 2, 2026
Avg Cost/Share
$17.27
Shares
2,199
Total Value
$37,976.73
Owned After
88,941
SEC Form 4
Livingston Mark S.
Sell
CHIEF FINANCIAL OFFICER
PGNY Dec 11, 2025
Avg Cost/Share
$25.50
Shares
459
Total Value
$11,704.50
Owned After
46,983
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Swartz Allison | PGNY | EVP, GC | Mar 4, 2026 | Sell | $17.54 | 599 | $10,506.46 | 88,941 | |
| Swartz Allison | PGNY | EVP, GC | Mar 3, 2026 | Sell | $17.40 | 4,657 | $81,029.80 | 88,941 | |
| Swartz Allison | PGNY | EVP, GC | Mar 2, 2026 | Sell | $17.27 | 2,199 | $37,976.73 | 88,941 | |
| Livingston Mark S. | PGNY | CHIEF FINANCIAL OFFICER | Dec 11, 2025 | Sell | $25.50 | 459 | $11,704.50 | 46,983 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
AI Prediction SELL
1D
-5.66%
$20.99
5D
-8.21%
$20.42
20D
-4.58%
$21.23
Price: $22.25 Prob +5D: 0% AUC: 1.000
0001551306-26-000012
pgny-202602260001551306false00015513062026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026
Progyny, Inc. (Exact name of Registrant as Specified in Charter)
Delaware 001-39100 27-2220139
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
1359 Broadway New York, New York 10018
(Address of Principal Executive Offices) (Zip Code)
(212) 888-3124 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
PGNY
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition and Item 7.01 Regulation FD Disclosure.
On February 26, 2026, Progyny, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
In addition to the press release, a supplemental earnings presentation will be made available on the Company’s investor relations page at investors.progyny.com. A copy of this supplemental earnings presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.
The information furnished under Item 2.02 and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release of Progyny, Inc. dated February 26, 2026
99.2 Fourth Quarter 2025 Earnings Supplemental Presentation
104 Cover Page Interactive Data File (embedded within Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Progyny, Inc.
Dated: February 26, 2026
By: /s/ Peter Anevski
Peter Anevski
Chief Executive Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
AI Prediction SELL
1D
-5.66%
$20.99
5D
-8.21%
$20.42
20D
-4.58%
$21.23
Price: $22.25 Prob +5D: 0% AUC: 1.000
0001551306-26-000009
pgny-202601120001551306false00015513062026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026
Progyny, Inc. (Exact name of Registrant as Specified in Charter)
Delaware001-3910027-2220139 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
1359 Broadway New York, New York 10018 (Address of Principal Executive Offices)(Zip Code)
(212) 888-3124 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share PGNYThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 12, 2026, Progyny, Inc. (the “Company”) issued a press release to update the Company’s previously issued financial guidance for the three months and year ending December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release of Progyny, Inc. dated January 12, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Progyny, Inc.
Dated: January 12, 2026 By: /s/ Peter Anevski Peter Anevski Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0001551306-25-000186
pgny-202511060001551306false00015513062025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025
Progyny, Inc. (Exact Name of Registrant as Specified in Charter)
Delaware001-3910027-2220139 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
1359 Broadway New York, New York 10018 (Address of Principal Executive Offices)(Zip Code)
(212) 888-3124 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share PGNYThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition and Item 7.01 Regulation FD Disclosure.
On November 6, 2025, Progyny, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
In addition to the press release, a supplemental earnings presentation will be made available on the Company’s investor relations page at investors.progyny.com. A copy of this supplemental earnings presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.
The information furnished under Item 2.02 and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release of Progyny, Inc. dated November 6, 2025
99.2Third Quarter Earnings Supplemental Presentation
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Progyny, Inc.
Date: November 6, 2025 By: /s/ Peter Anevski Peter Anevski Chief Executive Officer
Latest Progyny Inc. News
PGNY Breaking Stock News: Dive into PGNY Ticker-Specific Updates for Smart Investing
GuruFocus.com
Progyny Inc (PGNY) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...
📊
AI Sentiment
Positive
7/10
Compare PGNY vs Leading Stocks
See how PGNY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PGNY Progyny Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.